Medicare Enrolled
Dr. Sanober Kable, MD
Critical Care Medicine · Denison, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kable from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kable?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kable
Dr. Sanober Kable is a critical care medicine specialist in Denison, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Kable performed 40,935 Medicare services across 4,921 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kable received a total of $239,350 from 58 pharmaceutical and/or device companies across 1728 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in critical care medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kable is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 0% volume in TX
$239,350 industry payments
Medicare Practice Summary
Medicare Utilization ↗40,935
Medicare services
Top 0% in TX for critical care medicine
4,921
Unique beneficiaries
$35
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,154 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Omalizumab injection (Xolair) for asthma/allergy | 17,117 | $30 | $40 |
| Injection, mepolizumab, 1 mg | 14,270 | $23 | $60 |
| Injection, benralizumab, 1 mg | 1,740 | $132 | $250 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,327 | $93 | $210 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
974 | $11 | $79 |
| Allergy skin test A diagnostic test performed to identify specific allergies by applying or introducing allergenic extracts to the body. The procedure measures the patient's immune response to various potential allergens. |
937 | $3 | $10 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
690 | $65 | $150 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
660 | $41 | $149 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
631 | $39 | $150 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
549 | $24 | $100 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
449 | $28 | $150 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
284 | $59 | $140 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
221 | $20 | $100 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
201 | $123 | $320 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
140 | $78 | $210 |
| Methylprednisolone acetate injection, 20 mg A 20 mg injection of methylprednisolone acetate, a corticosteroid medication. This code specifies the drug and dosage administered. |
130 | $4 | $30 |
| Bronchial irrigation and suction for cell collection This procedure uses an endoscope to flush and suction the lung airways in order to collect cells for testing. |
89 | $14 | $600 |
| Sleep study with continuous airway pressure, age 6+ A sleep study conducted in a sleep lab that monitors breathing and other body functions while administering continuous airway pressure. This test is performed on patients aged 6 years or older. |
85 | $95 | $889 |
| Lung biopsy via endoscope, 1 lobe A procedure to remove a small sample of lung tissue from one lobe using an endoscope for examination. |
82 | $94 | $700 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
68 | $95 | $270 |
| Sleep study in sleep lab (age 6+) An overnight test conducted in a sleep laboratory to monitor sleep patterns and bodily functions in patients aged 6 years or older. |
64 | $90 | $240 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
42 | $0 | $35 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
35 | $92 | $205 |
| Endoscopic needle biopsy of windpipe, airway, or lung A procedure where a needle is inserted through an endoscope to collect tissue samples from the windpipe, airway, or lung. |
32 | $125 | $1,125 |
| Sleep study with heart rate and breathing monitoring A sleep study that monitors heart rate, breathing, airflow, and physical effort during sleep. |
26 | $66 | $456 |
| Bronchoscopy A procedure to examine the airways inside the lungs using a thin, flexible tube with a camera. |
25 | $8 | $479 |
| Computer-assisted navigation of lung airways This procedure uses computer technology to guide an endoscope through the airways of the lungs for precise navigation. |
24 | $73 | $1,998 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
20 | $54 | $200 |
| Right heart catheterization A procedure where a thin, flexible tube is inserted into the right side of the heart to measure pressure and oxygen levels. |
12 | $98 | $1,470 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
11 | $134 | $400 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$239,350
Total received (2018-2024)
Avg $34,193/year across 7 years
Top 1% in TX for critical care medicine
58
Companies
1,728
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$213,419 (89.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$16,403 (6.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$9,528 (4.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$52,440
2023
$38,493
2022
$26,478
2021
$32,967
2020
$27,550
2019
$21,755
2018
$39,665
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$81,981
AstraZeneca Pharmaceuticals LP
$55,022
GENZYME CORPORATION
$30,689
Sunovion Pharmaceuticals Inc.
$22,327
JAZZ PHARMACEUTICALS INC.
$10,205
United Therapeutics Corporation
$9,447
Bayer HealthCare Pharmaceuticals Inc.
$9,071
Intuitive Surgical, Inc.
$4,840
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,901
Mylan Specialty L.P.
$1,371
Actelion Pharmaceuticals US, Inc.
$1,364
Boston Scientific Corporation
$1,271
ZOLL Respicardia, Inc.
$1,189
Takeda Pharmaceuticals U.S.A., Inc.
$940
Electromed, Inc.
$912
Regeneron Healthcare Solutions, Inc.
$731
Genentech USA, Inc.
$641
Bayer Healthcare Pharmaceuticals Inc.
$612
Grifols USA, LLC
$568
Novartis Pharmaceuticals Corporation
$411
Insmed, Inc.
$365
Pulmonx Corporation
$329
Ethicon Inc.
$256
Jazz Pharmaceuticals Inc.
$254
Philips Electronics North America Corporation
$240
Mallinckrodt LLC
$227
Amgen Inc.
$214
Baxter Healthcare
$214
Janssen Pharmaceuticals, Inc
$192
Advanced Respiratory, Inc
$173
Veran Medical Technologies, Inc.
$158
Tactile Systems Technology Inc
$145
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$98
Axsome Therapeutics, Inc.
$93
ADVANCED RESPIRATORY, INC
$87
Gilead Sciences, Inc.
$81
Harmony Biosciences LLC
$74
HARMONY BIOSCIENCES LLC
$66
CSL Behring
$64
PFIZER INC.
$61
Eisai Inc.
$47
Mallinckrodt Hospital Products Inc.
$45
Shire North American Group Inc
$43
Mallinckrodt Enterprises LLC
$41
Exeltis, USA Inc.
$39
Circassia Pharmaceuticals Inc
$33
Vapotherm Inc
$32
Merck Sharp & Dohme LLC
$26
Supernus Pharmaceuticals, Inc.
$22
Avadel CNS Pharmaceuticals, LLC
$21
Covis Pharma GmBH
$19
Cumberland Pharmaceuticals, Inc.
$19
Merck Sharp & Dohme Corporation
$16
Inogen, Inc.
$16
E.R. Squibb & Sons, L.L.C.
$14
Pernix Therapeutics Holdings, Inc.
$14
Currax Pharmaceuticals LLC
$11
INOGEN, INC.
$7
Top 3 companies account for 70.1% of total payments
Associated products mentioned in payments ›
(8874) inCourage · ACQUIRE · ACTHAR · AIRSUPRA · ANORO · ANORO ELLIPTA · APTIOM · AREXVY · Adempas · Arikayce · BEVESPI AEROSPHERE · BREO · BREO ELLIPTA · BREZTRI · BREZTRI AEROSPHERE · BROVANA · Belviq · CHANTIX · CHARTIS CATHETER · CONTRAVE · CUVITRU · DUPIXENT · Da Vinci Surgical System · Dayvigo · ELIQUIS · Esbriet · FARXIGA · FASENRA · Flexitouch Plus · GENERAL PULMONARY · GLASSIA · Hillrom - Vest System Model 105 Home Care · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · ION · InogenOne · LONHALA MAGNAIR · LUMRYZ · Letairis · LifeVest · Monarch Platform · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · PURIFIED CORTROPHIN GEL · Perforomist · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · REMODULIN · Respiratoriy Care Undiv · SEEBRI NEOHALER · SILENOR · SMARTVEST · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Spin · Sunosi · TAGRISSO · TEZSPIRE · TRELEGY ELLIPTA · TROKENDI XR · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · ULTRAFLEX · UPTRAVI · UTIBRON NEOHALER · Utibron · Vibativ · WAKIX · Wakix · Wellcentive Undiv · XARELTO · XOLAIR · XYREM · XYWAV · Xofluza · Xolair · Xyrem · YUPELRI · Yupelri · Zemaira · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (89%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in critical care medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for critical care medicine in TX.
Equivalent to $585 per 100 Medicare services performed
Geographic Context
Critical care medicines within 10 mi
3
Per 100K population
2.1
County median income
$70,455
Nearest hospital
TEXOMA MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kable is a mixed practice specialist, with above-average Medicare volume (top 0% in TX), with speaking/promotional industry engagement in the top 1% of TX peers, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kable experienced with omalizumab injection (xolair) for asthma/allergy?
Based on Medicare claims data, Dr. Kable performed 17,117 omalizumab injection (xolair) for asthma/allergy services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kable receive payments from pharmaceutical companies?
Yes. Dr. Kable received a total of $239,350 from 58 companies across 1,728 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kable's costs compare to other critical care medicines in Denison?
Dr. Kable's average Medicare payment per service is $35. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kable) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Critical Care Medicines in Denison
Browse critical care medicines in Denison ranked by procedure volume and transparency data.
Highest volume
Top Critical Care Medicines in TX
Critical care medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Critical Care Medicines in TX
Which TX critical care medicines receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology